Teva’s MS Drug Misses Study Goal
Teva Pharmaceutical Industries Ltd. said its experimental drug laquinimod, an oral treatment for multiple sclerosis, did not reduce patients'' annual relapse rate in a late-stage clinical trial, Forbes reported. Shares of Teva, which also makes the injectable MS drug Copaxone, lost $2.69, or 5.8 percent, to $43.95 in afternoon trading. The results showed that laquinimod was not more effective than a placebo. The study involved 1,331 patients.